Henrietta Lacks’s family sues another pharmaceutical company
By Clarence Williams,
The Washington Post
| 08. 10. 2023
The heirs of Henrietta Lacks, the Black woman who died in the 1950s and whose cells have been reproduced for decades in scientific research, filed suit Thursday in Baltimore federal court alleging that a pharmaceutical company profited from using cells without the consent of Lacks or her family.
The action comes almost two weeks after Lacks’s descendants settled litigation with another biotech company that had allegedly profited from the cells despite knowing that they were extracted without her consent. Terms of the litigation were not released.
Thursday’s suit asks a court to force Ultragenyx, a California-based company that focuses on the development and commercialization of products for rare and genetic diseases, to stop the use of Lacks’s cell line without the permission of her family; to create a “trust” for the cells in possession; to reveal the profits earned from use of the cells; and to provide financial relief.
Lacks was a Baltimore mother of five when she was diagnosed with cervical cancer in 1951 at age 31. A Johns Hopkins Hospital doctor took a sample from her tumor without...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...